李发英,于国英

在探讨全球性公共卫生问题慢性丙型肝炎（CHC）时，我们需要关注病毒基因型的多样性及其在疾病进程中的作用。特别是基因3型HCV，由于其全球范围内的广泛分布和较高的感染率，成为了研究的焦点。HCV的治疗历程不断进化，尤其是随着直接抗病毒药物（DAAs）的出现，治疗效果有了显著提升。然而，基因3型HCV感染者对治疗的反应表现出复杂的图景，这可能与多种因素如宿主遗传、病毒特性及治疗方案的差异有关。进一步的研究发现，基因3型HCV感染者对相同治疗方案的反应存在变异，这种差异性的治疗反应提示我们需要除了考虑药物的直接抗病毒效果外，还需关注宿主因素、伴随疾病以及病毒本身特征的影响。举例来说，患者肝脏纤维化程度、代谢状态和免疫响应等因素可能会影响治疗结果。

慢性丙型肝炎；基因3型；脂肪变性；DAA

[1] Guidelines for the prevention and treatment of hepatitis C(2019 version).Zhonghua Gan Zang Bing Za Zhi 2019;27(12):962–979. [2] Messina JP,Humphreys I,Flaxman A,et al.Global distribution and prevalence of hepatitis C virus genotypes.Hepatology.2015;61(1):77-87. [3] Petruzziello A,Loquercio G,Sabatino R,et al.Prevalence of Hepatitis C virus genotypes in nine selected European countries:A systematic review.J Clin Lab Anal.2019;33(5):e22876. [4] Global prevalence and genotype distribution of hepatitis C virus infection in 2015:a modelling study.Lancet Gastroenterol Hepatol.2017;2(3):161-176. [5] Messina JP,Humphreys I,Flaxman A,et al.Global distribution and prevalence of hepatitis C virus genotypes.Hepatology.2015;61(1):77-87. [6] Chen Y,Yu C,Yin X,et al.Hepatitis C virus genotypes and subtypes circulating in Mainland China.Emerg Microbes Infect.2017;6(11):e95. [7] Zhang Y,Chen LM,He M.Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution.Virol J.2017;14(1):41. [8] Ju W,Yang S,Feng S,Wang Q,Liu S,Xing H,et al.Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients:nation-wide spread of HCV genotypes 3 and 6.Virol J 2015;12:109. [9] Bochud PY,Cai T,Overbeck K,et al.Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.J Hepatol.2009;51(4):655-66. [10] Welzel TM,Bhardwaj N,Hedskog C,et al.Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.J Hepatol.2017;67(2):224-236. [11] Kattakuzhy S,Levy R,Rosenthal E,et al.Hepatitis C genotype 3 disease.Hepatol Int.2016;10(6):861-870. [12] d'Avigdor WMH,Budzinska MA,Lee M,et al.Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver.Sci Rep.2019;9(1):10596. [13] Rubbia-Brandt L,Quadri R,Abid K,et al.Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.J Hepatol.2000;33(1):106-15. [14] Mirandola S,Realdon S,Iqbal J,et al.Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis.Gastroenterology.2006;130(6):1661-9. [15] de Gottardi A,Pazienza V,Pugnale P,et al.Peroxisome proliferator-activated receptor-alpha and-gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther.2006;23(1):107-14. [16] Jackel-Cram C,Qiao L,Xiang Z,et al.Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway.J Gen Virol.2010;91(Pt 6):1388-95. [17] Perlemuter G,Sabile A,Letteron P,V ona G,Topilco A,Chretien Y,et al.Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion:a model of viral-related steatosis.FASEB journal:official publication of the Federation of American Societies for Experimental Biology.2002;16(2):185–94. [18] Mirandola S,Realdon S,Iqbal J,Gerotto M,Dal Pero F,Bortoletto G,et al.Liver microsomaltriglyceride transfer protein is involved in hepatitis C liver steatosis.Gastroenterology.2006;130(6):1661–9. [19] de Gottardi A,Pazienza V,Pugnale P,et al.Peroxisome proliferator-activated receptor-alpha and-gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther.2006;23(1):107-14. [20] 韦新焕,杜晓菲,柳雅立等.索磷布韦/维帕他韦治疗静脉药瘾基因3型丙型病毒性肝炎持续病毒学应答的真实世界研究[J].临床药物治疗杂志,2021,19(12):16-21. [21] Lawitz E,Mangia A,Wyles D,et al.Sofosbuvir for previously untreated chronic hepatitis C infection.N Engl J Med.2013;368(20):1878-87. [22] Foster GR,Pianko S,Brown A,et al.Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.Gastroenterology.2015;149(6):1462-70. [23] Nelson DR,Cooper JN,Lalezari JP,Lawitz E,Pockros PJ,Gitlin N,et al.All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:ALL Y-3 phase III study.Hepatology(Baltimore,Md).2015;61(4):1127–35. [24] Gower E,Estes C,Blach S,et al.Global epidemiology and genotype distribution of the hepatitis C virus infection.J Hepatol.2014;61(1 Suppl):S45-57. [25] Bruggmann P,Berg T,Øvrehus AL,et al.Historical epidemiology of hepatitis C virus(HCV)in selected countries.J Viral Hepat.2014;21 Suppl 1:5-33. [26] Probst A,Dang T,Bochud M,et al.Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis.J Viral Hepat.2011;18(11):745-59. [27] Leandro G,Mangia A,Hui J,et al.Relationship between steatosis,inflammation,and fibrosis in chronic hepatitis C:a meta-analysis of individual patient data.Gastroenterology.2006;130(6):1636-42. [28] Roingeard P.Hepatitis C virus diversity and hepatic steatosis.J Viral Hepat.2013;20(2):77-84. [29] 唐巧,胡鹏.基因3型丙型肝炎病毒感染的抗病毒治疗方案、临床效果及影响因素[J].保健医学研究与实践,2021,18(05):181-185. [30] Syed GH,Amako Y,Siddiqui A.Hepatitis C virus hijacks host lipid metabolism.Trends in endocrinology and metabolism:TEM.2010;21(1):33–40. [31] Mirandola S,Realdon S,Iqbal J,et al.Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis.Gastroenterology.2006;130(6):1661-9. [32] Shi ST,Polyak SJ,Tu H,et al.Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins.Virology.2002;292(2):198-210. [33] Sheridan DA,Shawa IT,Thomas EL,et al.Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis.Sci Rep.2022;12(1):5562. [34] 赵智蓉.索磷布韦维帕他韦联合利巴韦林治疗基因3型慢性丙型肝炎疗效和安全性研究[D].大理大学,2021. [35] Jackel-Cram C,Babiuk LA,Liu Q.Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein:genotype-3a core has a stronger effect than genotype-1b core.J Hepatol.2007; 46(6):999-1008. [36] Gane EJ,Kowdley KV,Pound D,et al.Efficacy of Sofosbuvir,Velpatasvir,and GS-9857 in Patients With Hepatitis C Virus Genotype 2,3,4,or 6 Infections in an Open-Label,Phase 2 Trial. Gastroenterology.2016;151(5):902-909. [37] Jackel-Cram C,Qiao L,Xiang Z,et al.Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway.J Gen Virol.2010;91(Pt 6):1388-95. [38] 赵智蓉,李海雯,李晓非等.索磷布韦维帕他韦联合利巴韦林治疗基因3型慢性丙肝患者的疗效与安全性[J].昆明医科大学学报,2021,42(03):98-103. [39] de Gottardi A,Pazienza V,Pugnale P,et al.Peroxisome proliferator-activated receptor-alpha and-gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther.2006;23(1):107-14. [40] Mangia A,Santoro R,Minerva N,et al.Peginterferon alfa-2b and ribavirin for 12 vs.24 weeks in HCV genotype 2 or 3.N Engl J Med.2005;352(25):2609-17. [41] 江梦凤.基因3型丙型肝炎患者的流行病学特征和DAAs治疗疗效及安全性分析[D].广西医科大学,2020. [42] Lawitz E,Mangia A,Wyles D,et al.Sofosbuvir for previously untreated chronic hepatitis C infection.N Engl J Med.2013;368(20):1878-87. [43] Zeuzem S,Dusheiko GM,Salupere R,et al.Sofosbuvir and ribavirin in HCV genotypes 2 and 3.N Engl J Med.2014;370(21):1993-2001. [44] EASL Recommendations on Treatment of Hepatitis C 2015.J Hepatol.2015;63(1):199-236. [45] 吴红琴.索菲布韦联合达卡他韦加或者不加利巴韦林治疗基因3型慢性丙肝疗效及安全性的meta分析[D].南昌大学,2018. [46] Leroy V,Angus P,Bronowicki JP,et al.Daclatasvir,sofosbuvir,and ribavirin for hepatitis C virus genotype 3 and advanced liver disease:A randomized phase III study(ALLY-3+).Hepatology.2016;63(5):1430-41. [47] Foster GR,Afdhal N,Roberts SK,et al.Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.N Engl J Med.2015;373(27):2608-17. [48] Gane EJ,Schwabe C,Hyland RH,et al.Efficacy of the Combination of Sofosbuvir,Velpatasvir,and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.Gastroenterology.2016;151(3):448-456.e1. [49] Sarrazin C.The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.J Hepatol.2016;64(2):486-504.

点击下载PDF